A huge congratulations to our partners at eXmoor Pharma! Their state-of-the-art advanced therapies manufacturing facility in Bristol has just been licensed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture GMP-grade cell and gene therapy materials for use in clinical trials. eXmoor now offers a full set of development, manufacturing, and consulting services to CGT innovators.
We are delighted to announce that we have secured our MIA(IMP) license from the MHRA for the manufacture of cell & gene therapies for clinical trials. Our 65,000 sq. ft Cell & Gene Therapy Centre provides GMP cleanrooms and fill finish capabilities for autologous & allogenic cell therapies, viral vectors, RNA and other technologies! “This marks the beginning of a new era of growth for eXmoor pharma, now offering a complete set of development, manufacturing and expert consulting services that support cell and gene therapy developers from research to the market,” said Angela Osborne, CEO. “As we develop new partnerships, we will expand GMP operations to pivotal and commercial scale within the facility that is designed to increase cleanroom capacity quickly and easily – but we will retain the same underlying commitment to collaboration and focus on achieving our client's goals.” https://lnkd.in/eUZ9uGPp